# AlveoGene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alveogene

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.alveogene.com
- Total disclosed funding: $2.2M
- Latest round: Seed (Jul 24, 2023)
- Investors on record: 3

## About

Based in Oxford, UK, and founded in 2022, AlveoGene operates as a biotechnology research firm focused on finding remedies for rare respiratory diseases using inhaled gene therapy. In September 2023, the firm raised an amount of Seed funding from investors Harrington Discovery Institute, Old College Capital, and Oxford Sciences Enterprises.

The company offers treatment for the rare respiratory diseases. With the exception of using the CFTR gene, which is mutated in cystic fibrosis, it retains the exclusive license to a proprietary and validated next-generation lentiviral delivery platform created by the GTC for the treatment of respiratory disorders with high unmet needs.

## Funding rounds

- Seed, Jul 24, 2023, $2.2M — Old College Capital, Oxford Sciences Enterprises, Harrington Discovery Institute

## Investors

- Old College Capital (https://capitalatlas.ai/funds/old-college-capital) — Seed
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Seed
- Harrington Discovery Institute — Seed